ClinicalTrials.gg
RecruitingNCT07410039ETA/PETA-NMOSDUpdated Mar 12, 2026

Therapy in the Acute Phase of NMOSD: A Multicenter Prospective Real-World Study

A Phase 4 interventional study of Eculizumab+IVMP and IVIG+IVMP in Neuromyelitis Optica Spectrum Disorder Attack, sponsored by Chinese PLA General Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-03-12.

Sponsored by Chinese PLA General Hospital · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 72 studies in Neuromyelitis Optica with a site in China — 37 open to participants now, 43 under way, 7 of them phase 3. Neuromyelitis Optica · China.

Planned enrollment
2nd of 51
200 · median 23
Started
2026
with 11 others
Phase 4
6 of 72
3 open now
Primary completion
2027-06
later than 22 of 42 live
Registered
66th of 72
by date
Lead sponsor
4 of 72
Chinese PLA General Hospital

Among the 72 studies in Neuromyelitis Optica with a site in China, this one is the 2nd largest by planned enrollment of the 51 interventional ones that give a count, is one of 12 that started in 2026, is one of 6 in phase 4, reaches primary completion later than 22 of the 42 other live ones, and was the 66th registered.

Neuromyelitis Optica

178 studies on the registry are indexed under Neuromyelitis Optica; 78 are open to participants now.

Browse Neuromyelitis Optica studies →

Open to participants now

37 of the 72 studies in Neuromyelitis Optica with a site in China are open now. Recruiting first, the newest first:

31 more — sign in →

All 37 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 50 Neuromyelitis Optica studies recruiting now, 29 (58%) set no upper age limit and 16 (32%) stop at 75 or younger; 11 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 72 studies in Neuromyelitis Optica with a site in China, or all of them as a file.
02

Study summary

This project is a multi-center, prospective, real-world cohort study that collects clinical data of Chinese patients with AQP4-positive NMOSD in the acute stage. It comprehensively assesses the clinical outcomes of the patients and aims to compare the clinical efficacy and safety of icoxib as a combined add-on treatment versus simple hormone shock therapy during the acute phase of NMOSD.Using simple hormone shock therapy (IVMP) as the control group, the efficacy and safety of etanercept treatment in the acute attack phase of Chinese patients with AQP4-positive neuromyelitis optica spectrum disorder (NMOSD) were evaluated.

Read the detailed description

Patients who met the inclusion and exclusion criteria were divided into three groups for their acute-phase treatment based on their treatment preferences:

  1. Eculizumab plus treatment group: Eculizumab + IVMP (intravenous methylprednisolone pulse therapy)
  2. Human immunoglobulin addition treatment group: IVIG + IVMP
  3. Single IVMP treatment group: IVMP
03

Conditions studied

  • Neuromyelitis Optica Spectrum Disorder Attack

Browse trials for

Keywords

  • Neuromyelitis Optica Spectrum Disorder (NMOSD)
  • acute attack phase
  • eculizumab add-on therapy
  • AQP4-IgG positive
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age: 18 - 65 years old, gender not restricted.
  2. Patients who meet the diagnostic criteria for NMOSD as set by the International Panel for NMO Diagnosis (IPND) in 2015, and have positive serum AQP4-IgG (by CBA method or live cell method).
  3. Acute phase of NMOSD-ON, defined as new or worsening optic nerve dysfunction (visual acuity decline accompanied or not by eye pain and visual field defect), with an onset duration of ≤ 21 days, and clear evidence of new or recurrent optic nerve damage on imaging (new or expanded T2WI lesions, with enhancement); the best corrected visual acuity (BCVA) of the affected eye during the acute phase of NMOSD-ON (if both eyes are affected simultaneously, the worse eye is considered) drops from above 0.3 to ≤ 0.1.
  4. Acute phase of NMOSD-TM, defined as new or worsening spinal cord dysfunction (limb weakness or numbness, accompanied or not by urinary and defecation disorders), with an onset duration of ≤ 21 days, and clear evidence of new or recurrent spinal cord damage on imaging (new or expanded T2WI lesions, with enhancement); the EDSS score during the acute phase of NMOSD-TM increases from ≤ 4.0 to ≥ 6.0.
  5. Clinical onset and recurrence determination requires unanimous judgment by each center and the center committee (an independent group of 3 people).
  6. Agree to receive meningococcal vaccine or use eculizumab during and 2 weeks after the medication.
  7. Sign the .

Exclusion criteria

Exclusion Criteria:

  1. Damage to the optic nerve or spinal cord caused by other non-NMOSD-related factors.
  2. Abnormal laboratory indicators that need to be excluded from the subjects include, but are not limited to the following indicators:

    Neutrophils \< 1.5 × 109/L, \< 90g/L, count \< 75 × 109/L; Serum creatinine > 1.5 × , Total > 1.5 × ULN, (AST) > 1.5 × ULN, Alanine aminotransferase (ALT) > 1.5 × ULN, Alkaline phosphatase > 2 × ULN ; > 8% (for diabetic patients); \< 60 mL/minute/1.73m2.

  3. Pregnant or lactating women, as well as those planning to become pregnant during the study period.
  4. Those who have received PE/IA/IVIG/FcRn/B-cell deletion/C5/IL-6 treatment within 1 month before enrollment.
  5. Active infections: active , , syphilis or infection; active systemic infections or immunodeficiency diseases; unrelieved meningococcal infection of the meninges, or patients with severe infections that cannot use drugs.
  6. Patients with severe internal or external diseases (not limited to such as heart failure, unstable angina pectoris, respiratory failure, pulmonary insufficiency, cachexia, organ transplantation, etc.).
  7. Those who have had or currently have an untreated malignant tumor that is not well controlled.
  8. Patients with serious physical or mental diseases that may affect the smooth implementation of the study.
  9. Patients known to be allergic to monoclonal drugs, murine proteins or any .
  10. Patients who are intolerant to methylprednisolone or gamma globulin.
  11. Patients who cannot complete the magnetic resonance enhanced scan screening.
  12. Patients who are participating in other interventional clinical trials.
  13. Patients who cannot understand the questionnaire questions or cooperate with the questionnaire survey.
  14. Situations that the research team collectively deems unsuitable for participation in this study.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Active comparator
    Eculizumab+IVMP

    Eculizumab add-on treatment group: 1) The timing of eculizumab addition treatment should be within the 1000mg hormone treatment window; 2) Intravenous infusion of 900mg once a week for a total of 4 weeks; 3) The hormone administration regimen is the same as that of the hormone monotherapy group. All patients receiving eculizumab treatment are required to use prophylactic antibiotics and/or vaccination.

    Drug: Eculizumab+IVMP

  • Placebo comparator
    IVIG+IVMP

    Gamma globulin treatment group: 1) The administration of gamma globulin should occur within the 1000mg hormone treatment window; 2) The infusion dose is 0.4g/kg·d \* 5; 3) The hormone administration regimen is the same as that of the single hormone treatment group.

    Drug: IVIG+IVMP

  • Placebo comparator
    IVMP

    Single hormone shock therapy group: 1) Initiate hormone shock therapy during the acute phase of the attack (≤ 21 days); 2) Intravenous injection of methylprednisolone (IVMP) for 14 days: 1000 mg/day (5 days), 500 mg (3 days), 240 mg (3 days), 120 mg (3 days), then switch to oral administration.

    Drug: IVMP

Interventions

  • DrugEculizumab+IVMP

    Drug page: EculizumabStudies of EculizumabEculizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    (PETA-NMOSD Study): After the completion of intravenous methylprednisolone (IVMP), according to domestic treatment guidelines, it is necessary to continue immunosuppressive therapy and maintain it to prevent and reduce relapses. The specific treatment regimen is divided into four groups based on the patient's treatment preference.Eculizumab continuation treatment group,B-cell depletion treatment group,Mycophenolate mofetil group,Satellitezhuibao Treatment Group。

  • DrugIVIG+IVMP

    Patients who met the inclusion and exclusion criteria were divided into three groups for their acute-phase treatment based on their treatment preferences: 1. Eculizumab plus treatment group: Eculizumab + IVMP (intravenous methylprednisolone pulse therapy) 2. Human immunoglobulin addition treatment group: IVIG + IVMP 3. Single IVMP treatment group: IVMP After completing the acute-phase treatment, patients who met the inclusion and exclusion criteria entered the conversion treatment study (PETA-NMOSD) according to their treatment preferences, and were also divided into three groups: 1. B-cell depletion treatment group: Rituximab/Inalezumab + oral hormone sequential tapering 2. Methylprednisolone group: MMF + oral hormone sequential reduction and maintenance at a low dose 3. Eculizumab continuation treatment group: Eculizumab + oral hormone sequential tapering

  • DrugIVMP

    Single hormone shock therapy group: 1) Initiate hormone shock therapy during the acute phase of the attack (≤ 21 days); 2) Intravenous injection of methylprednisolone (IVMP) for 14 days: 1000 mg/day (5 days), 500 mg (3 days), 240 mg (3 days), 120 mg (3 days), then switch to oral administration.

06

What researchers measure

Primary outcomes

  1. Expanded Disability Status Scale score,EQ-5D-5L,

    Evaluate the EDSS score, EQ-5D-5L,

    Time frame: baseline (before the acute attack and before the initiation of this treatment), and after hormone treatment at weeks 1, 2, 3, 4, 8 and 12

  2. Expanded Disability Status Scale

    The EDSS score is evaluated by neurologists through a systematic examination. It is based on the assessment of the central nervous system functions (FS). Lower scores focus on evaluating functional impairments, such as numbness in the face or fingers, and visual disorders. Higher scores focus on evaluating functional impairments of the motor system, mainly difficulty in walking. The symptoms are scored from normal (0 points) to severe disability (5-6 points) across 8 systems (pyramidal tract function, cerebellar function, brainstem system function, sensory system function, bladder and rectal function, visual function, mental system function, and mobility function). The EDSS score mainly assesses the patient's neurological functional impairments and the severity of the disease. The score range is 0 to 10 points. The higher the score, the more severe the neurological functional impairment. A score of 0 indicates a normal healthy state, and a score of 10 indicates the death of MS.

    Time frame: Baseline (before the acute attack treatment), after 1st, 2nd, 3rd, 4th week of hormone treatment, 8th and 12th week

07

Study locations

1 of 1 sites recruiting
  • the First Medical Center of Chinese PLA General Hospital
    Beijing, China
    Recruiting
    • Dehui huang · Contacthuangdehui@gmail.com · +86-13911079787
    • lei wu, Associate Chief Physician · Contact
    • Dehui huang, Chief Physician · Principal investigator
    • lei wu, Associate Chief Physician · Sub investigator
08

References and documents

Related links

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2026 (actual). Primary completion is estimated for Jun 2027, 16 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 6, 2026
First posted
Feb 13, 2026
StartActual
Feb 1, 2026
Primary completionEst.
Jun 30, 2027
CompletionEst.
Jun 30, 2029
Last update
Mar 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07410039
Responsible party
Zhang Li (Associate Chief Physician of Neuroimmunology Subspecialty, Chinese PLA General Hospital) — Principal investigator
First posted
Feb 13, 2026
Start date
Feb 1, 2026
Primary completion
Jun 30, 2027 (estimated)
Completion
Jun 30, 2029 (estimated)
Last update
Mar 12, 2026

Study contacts

Dehui huang, Doctoral degree
Contact
huangdehui@gmail.com
+86-13911079787

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eculizumab

Start the discussion